Jaguar primed to pounce with portfolio of early stage gene therapies

Feb. 25, 2021

Jaguar Gene Therapy LLC, a startup reuniting former Avexis Inc. executives to develop a portfolio of potential treatments for severe genetic diseases, announced its public debut Feb. 25 with more than $40 million in series A financing from co-creator Deerfield Management.

BioWorld Financings Gene therapy Series A

Free access to BioWorld coronavirus articles

BioWorld

The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

Today's news in brief

BioWorld

BioWorld briefs for April 9.

Somalogic to merge with CM Life Sciences II SPAC, as trendy IPO path continues

BioWorld MedTech

Somalogic Inc. has agreed to go public via a merger with blank-check company CM Life Sciences II. Upon closing, CMLS II – a special purpose acquisition company...

Today's news in brief

BioWorld MedTech

BioWorld MedTech's briefs for April 9.

Global cases rise, but more weapons advance to combat COVID-19

BioWorld

As COVID-19 vaccinations continue to roll out, momentum builds with strong phase III data for what could become the fourth and fifth walls of defense in the U.S.